leisure time -WSS

leisure time

author：knowledge 2025-09-01 15:20:26 - browse：9697

When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech supposed to bounce back?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain the story of Svetlana Mojsov, a chemist who played a vital role in the discovery of GLP-1 who has spent decades fighting for proper recognition. We also discuss the latest news in the life sciences, including the FDA hearing on a BrainStorm Cell Therapeutics’ polarizing ALS treatment, the end of the road for a once-vaunted drug developer, and the sorry state of biotech stocks.

For more on what we cover, here’s the Mojsov story; here’s the latest on BrainStorm; here’s the news on Intercept Pharmaceuticals; here’s more on the biotech market; here’s where you can find episodes of Color Code; and here’s where you can subscribe to the First Opinion Podcast.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Supreme Court strikes down use of affirmative action
Next article： Disclosing genetic information: not as worrisome as once feared

leisure time

WSS

Why are elite athletes different? Take a look at their microbes

U.K. not yet recommending Vertex's CRISPR therapy for sickle cell

Colonoscopy at 40? Study finds a possible benefit

3 hurdles to bringing medical devices to the U.S. market

Future doctors should be trained to promote social change

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

focus

leisure time

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Creating egg and sperm cells from stem cells raises ethical issues

Bright Health sells Medicare Advantage business to Molina

The battle over the Brookhaven Landfill on Long Island

Dobbs anniversary: the lost opportunity of abortion as health care

The story of mRNA: From a loose idea to a tool that may help curb Covid

Novavax promises a turnaround & Lilly roils the obesity market

Study: Lilly Alzheimer's therapy slowed patients' cognitive decline

focus

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Cloning humans is technically possible. It's curious no one has tried

Orchard's therapy for neuron disease in children wins FDA approval

U.K. researchers warn about biases in medical devices, algorithms

The strategy behind pharma's lawsuits over drug pricing reform

Donald Trump's relentless attacks on special counsel Jack Smith

entertainment

explore

leisure time

focus